Introduction
Structure-based reverse vaccinology uses functional antibodies to identify critical epitopes in their native 3-D conformations, essential for effective vaccine development. However, challenges such as conformational epitope mapping and the immunodominance of diverse bacterial antigens have limited its success against complex bacterial pathogens. Our study introduces a novel multimodal protein mass spectrometry (MS) approach to characterise antigen-antibody complexes under near-native conditions, using streptolysin O (SLO) from Group A Streptococcus as a showcase.
Methods
We identified an uncharacterised monoclonal antibody that neutralises SLO-induced haemolysis. Using de novo MS sequencing, we determined the full amino acid sequences of the antibody light and heavy chains. Chemical cross-linking MS provided informative distance constraints within SLO-antibody complexes, and integrative computational modelling revealed a conformational epitope in domain 3 of SLO. This was further validated through hydrogen/deuterium exchange MS and reverse engineering of the targeted epitope.
Results
Our findings show that protective antibodies are able to neutralise SLO-induced cytolysis by targeting a conserved conformational epitope in domain 3, likely preventing SLO oligomerisation and subsequent pore formation on the cellular membrane. This epitope, present in over 98% of sequenced Group A Streptococcus isolates, provides a foundation for therapeutic and vaccine development against severe streptococcal infections.
Conclusion
Taken together, this result with the extended application of this methodology to another significant pneumococcal antigen underscores the importance of identifying and distinguishing structural epitopes for immune protection. Multimodal MS holds great potential in accelerating the design of next-generation epitope-targeting therapies and vaccines.